1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide | 473881-99-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide
• 英文别名: 2-[3-(5-benzyl-1H-pyrazol-3-yl)pyridin-1-ium-1-yl]-1-phenylethanone;bromide
• CAS: 473881-99-1
• 化学式: Br*C₂₃H₂₀N₃O
• 分子量: 434.335
• InChiKey: DABSWPCGPLOFSY-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof
  申请人：TORRENT PHARMACEUTICALS LTD.

  公开号：US20030045554A1

  公开（公告）日：2003-03-06

  The invention discloses a new clause of a five membered heterocylic ring compounds of general formula 1 1 and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and/or free radicals in the body cells.

  本发明公开了一种新的通式11的五元杂环化合物及其药学或美容学可接受的盐，其中R1、R2、R3、R4、R5、A、B、X和Y在说明书中定义。本发明还公开了制备这些化合物及其治疗和美容应用的方法，特别是在管理与衰老相关和糖尿病血管并发症方面。所述化合物通过AGE（高级糖基化终产物）断裂剂、AGE抑制剂和自由基清除剂的三重作用发挥作用，使它们在不同的治疗和美容应用中最为适用。本发明还公开了包含这些化合物的药物和化妆品组合物以及治疗由体细胞中AGE和/或自由基积累引起的疾病的方法。
• Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
  申请人：Torrent Pharmaceuticals Ltd.

  公开号：EP2659933A1

  公开（公告）日：2013-11-06

  The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.

  本发明涉及一种组合物，如一种组合制剂或药物组合物，其包含：(a) 式(I)和/或(II)化合物或其药学上可接受的盐；(b) 至少一种选自以下组别的治疗剂：抗高血压药；抗糖尿病药；降血脂药；抗血小板药；抗肥胖药；抗血栓药；治疗糖尿病血管并发症药；治疗心力衰竭药；或其药学上可接受的盐，可选择与药学上可接受的载体一起单独、同时或连续使用。本发明还涉及将此类组合物用于治疗包括人类在内的哺乳动物。 R1、R2、R3、R1、R2、R3、R4、R5、X、Y、A 和 B 以及 m 如说明书中所定义。
• HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS
  申请人：Torrent Pharmaceuticals Ltd

  公开号：EP1373263B1

  公开（公告）日：2004-10-27
• PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC
  申请人：Torrent Pharmaceuticals Ltd.

  公开号：EP2254563A2

  公开（公告）日：2010-12-01
• Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
  申请人：Dutt Chaitanya

  公开号：US20110034378A1

  公开（公告）日：2011-02-10

  The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R 1 , R 2 , R 3 , R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, A and B and m are as defined in the specification.